Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
NCT00150332
Last updated date
ABOUT THIS STUDY
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in
Japan
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Nosocomial Infections
Sex
Females and Males
Age
16 + years
Inclusion Criteria
Show details
- infection due to methicillin-resistant Staphylococcus aureus
Exclusion Criteria
Show details
- hypersensitivity to linezolid
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Nosocomial InfectionsLinezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
NCT00150332
- Kamogawa, Chiba
- Onga-gun, Fukuoka
- Sappopro, Hokkaido
- Sapporo, Hokkaido
- Moriya, Ibaraki
- Yokohama, Kanagawa
- Isahaya, Nagasaki
- Kurashiki, Okayama
- Kurashiki, Okayama
- Suita, Osaka
- Iruma-gun, Saitama
- Kodaira, Tokyo
- Fukuoka,
- Fukuoka,
- Hiroshima,
- Hiroshima,
- Kyoto,
- Nagasaki,
- Okayama,
- Okayama,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan | |||
Official Title ICMJE | Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial | |||
Brief Summary | Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Infections, Nosocomial | |||
Intervention ICMJE | Drug: linezolid | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 24 | |||
Original Enrollment ICMJE | 20 | |||
Actual Study Completion Date ICMJE | January 2006 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 16 Years and older (Child, Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Japan | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00150332 | |||
Other Study ID Numbers ICMJE | M12600067 A5951054 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | May 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |